CHENGDU, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE EuroNext: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced the implementation of a new sales and marketing strategy to categorize both distributors and hospital clients into three classes in order to optimize their sales and marketing structure.
The new strategy has classified distributors into three classes to optimize the clients from various distribution channels. The target goal is to develop 10 Class A nation-wide distributors with over $73.5 million annual sales, each which will contribute approximately 30% of Tianyin's annual sales, and 100 Class B distributors with annual sales between $29.4 million and $73.5 million each, which will contribute approximately 40% of annual sales. Class C distributors which have annual sales above $7 million and below $29.4 million, will be supplementary to class A and B clients and contribute approximately 30% of annual sales. The Company anticipates that this strategy will improve long-term relationships with strategic distribution partners, while optimizing and further diversifying the customer base.
The management also categorized hospital clients into three classes. Class
A hospitals are university hospitals with superior reputations which have over
$1.5 million of monthly medicine consumption; Class B hospitals have total
monthly medicine consumption between $1 million and $1.5 million, while Class
C hospitals have total monthly medicine consumption between $0.5 million and
$1 million. The sales team will mainly focus and spend most of their efforts
on Class A and Class B hospitals to generate major sales, but will dedicate
some time to Class C hospitals. The Company expects that sales from Class B
and Class C hospitals could be favorably promoted by the relations established
with major Class A hos
|SOURCE Tianyin Pharmaceutical, Co., Inc.|
Copyright©2008 PR Newswire.
All rights reserved